Trial Profile
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2018
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Ipsen
- 27 Jul 2018 Status changed from recruiting to completed.
- 26 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
- 26 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.